PLANETS
10.7.2024 20:01:29 CEST | Business Wire | Press release
teamLab Planets TOKYO DMM in Toyosu, Tokyo (hereinafter referred to as teamLab Planets), welcomed a total of 2,504,264 visitors from April 1, 2023, to March 31, 2024. This accomplishment has earned it recognition by GUINNESS WORLD RECORDS as the most visited museum (single art group) in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709556561/en/
teamLab Planets in Tokyo has been recognized by GUINNESS WORLD RECORDS™ as the most visited museum (single art group) in the world.(teamLab, Highlight video of teamLab Planets, Toyosu, Tokyo / Video: teamLab)
Additionally, teamLab Planets recorded a total of 2,412,495 visitors from January to December 2023 (*1). When compared to "The Art Newspaper Visitor Figures 2023" survey (*2), which compares visitor numbers at museums around the world, teamLab Planets significantly surpassed other single-artist museums, such as the Van Gogh Museum in Amsterdam (1,686,766 visitors) and the Picasso Museum in Barcelona (1,047,094 visitors).
teamLab Planets also ranked 5th in Google's "Year in Search 2023" for the "Most Popular Museums in the World" (*3), following the Louvre Museum (Paris), the British Museum (London), Musée d'Orsay (Paris), and the Natural History Museum (London).
This recognition marks the second GUINNESS WORLD RECORDS title for a teamLab museum, following the 2019 record set by teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Odaiba, Tokyo, which attracted 2,198,284 visitors (*4).
MASSIVE NEW AREA TO OPEN IN EARLY 2025
In early 2025, teamLab Planets will expand significantly with the addition of major new art spaces. The new area will feature the creative athletic space Athletics Forest, the co-creative educational project Future Park, as well as the Catching and Collecting Forest. The expansion will include over 10 art installations, greatly enhancing the teamLab Planets experience.
ATHLETICS FOREST
Athletics Forest is a creative athletic space based on the concept of understanding the world through the body and thinking about the world three-dimensionally. People immerse their entire body in the complex and physically challenging three-dimensional space of the interactive world.
"Humans perceive the world with their bodies and think with their bodies. When you explore a complex, three-dimensional world with your own body, you physically perceive the world three-dimensionally and in turn your thoughts become three-dimensional. We started this project, Athletics Forest, with the hopes to enhance three-dimensional and higher-dimensional thinking.
Spatial awareness is said to be correlated with innovation and creativity. I grew up in a rural area and played in the mountains, but in today's society and schools, the body is stationary. I think cities are surrounded too much by flat information such as books, TV, and smartphone screens. That is why we created a three-dimensional space that excessively demands the physical body. It is a space where people can perceive art with their physical bodies."
- teamLab Founder, Toshiyuki Inoko
Read more about the Athletics Forest concept:
https://www.teamlab.art/concept/athletics-forest/
FUTURE PARK
Future Park is an educational project based on the concept of collaborative creation (co-creation). It is an amusement park where people can enjoy creating the world freely with others.
An artwork comes to life through the process of people creating something together with others. As people continue to co-create, the artwork evolves endlessly.
Read more about the Future Park concept: https://www.teamlab.art/concept/future-park/
CATCHING AND COLLECTING FOREST
Catching and Collecting Forest is a new learning space based on the concept of Catch, Study, Release, in which people explore the world with their bodies, discovering, catching, and broadening their interests based on what they catch. Visitors explore with their smartphones, capture various creatures, study them, and create their very own collection book.
When a visitor uses the smartphone's camera to look at an animal moving in the space and shoots a Study Arrow at the animal in the camera's view, the arrow flies out from the phone into the real space. When the Study Arrow reaches the animal, it disappears from the space and is added to the visitor’s own smartphone collection. When a visitor swipes a captured animal towards a location seen in the app's camera, the animal is released and returns to that location.
"Physically exploring with others, discovering and catching something, then taking the chance to broaden interests based on what was caught. This is what we have been doing naturally over the long course of human history.
For humanity, the acts of catching and gathering are fun, educational, and part of life."
- teamLab Founder, Toshiyuki Inoko
Read more about the Catching and Collecting Forest concept:
https://www.teamlab.art/concept/catching/
About teamLab Planets
In Google’s "Year in Search 2023" annual search ranking, teamLab Planets ranked in the top 5 for "Most Popular Museums in the World" (*3). Amidst global museums with over a century of history, teamLab Planets is the sole museum from Japan to make the list. Additionally, it was named the most popular tourist attraction in Tokyo for two consecutive years by Honichi Lab (Visit Japan Lab)'s "Ranking of Popular Tourist Attractions Among Foreign Visitors: Tokyo Edition" (*5), chosen from a total of 2,662 attractions in Tokyo.
Furthermore, teamLab Planets has garnered international acclaim, including being the first in Japan to win "Asia's Leading Tourist Attraction 2023" at the World Travel Awards, often referred to as the Oscars of the travel industry.
teamLab Planets Concept
Together with Others, Immerse your Entire Body, Perceive with your Body, and Become One with the World
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
People go barefoot and immerse their entire bodies in the vast artworks together with others. The artworks change under the presence of people, blurring the perception of boundaries between the self and the works. Other people also create change in the artworks, blurring the boundaries between themselves and the works, and creating a continuity between the self, the art, and others.
Official website: teamlab.art.planets
Visitor Information
teamLab Planets TOKYO DMM
Toyosu, Tokyo (6-1-16 Toyosu, Koto-ku, Tokyo)
https://maps.app.goo.gl/QVs4a34HD9qnvjUo8
Hours: Daily 9:00 - 22:00
Closed: Wednesday, August 7; Wednesday, September 4
*Last entry one hour before closing.
*Hours are subject to change.
*Please check the official website for ticket prices.
teamLab Planets TOKYO DMM Ticket Store
https://teamlabplanets.dmm.com
Press Kit
https://www.dropbox.com/sh/ir7d2aui794eo6z/AAChbzX5wPsQm8cgkQ2ViFD4a?dl=0
*1. Based on teamLab Planets ticket user data (January 1, 2023 – December 31, 2023). |
*2. The Art Newspaper (2024) 'Visitor Figures 2023: The 100 most popular art museums in the world—blockbusters, bots and bounce-backs'. The Art Newspaper, 26 March. Available at:
|
*3 “artnet (2023) 'These Were the Most Popular Museums in the World, According to Google’s "Year in Search"'. artnet, 20 December. Available at:
|
*4 Press release on the world record for visitor numbers. Available at:
|
*5 Honichi Lab (2024) 'The Most Popular Tourist Spots in Tokyo Among Foreign Visitors in 2024: Asakusa Temple Ranks 3rd, and 1st Place is?'. Honichi Lab, 21 May. Available at:
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709556561/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
